Fig. 2.

Cytotoxicity of lapatinib in primary human hepatocytes and HepaRG cells. Cryopreserved plated human hepatocytes from two donors (Hu4246 and Hu1389) and HepaRG cells were treated with lapatinib (100 μM) for 24 hours. Cell viability was monitored using WST-1 assays, and viability is expressed as the percent viability compared with vehicle treatment. Data represent the mean ± S.D. of triplicate values for Hu4246 and Hu1389, and the mean ± S.D. of triplicate values from three independent experiments for HepaRG cells. *P < 0.05; **P < 0.01; ****P < 0.0001 compared with vehicle (unpaired t test, two-tailed P values).